Biogen Is Betting Big On Alzheimer's As Generics Slam Its Blockbusters

Biogen Is Betting Big On Alzheimer's As Generics Slam Its Blockbusters

Biogen stock tumbled Thursday despite offering a 2021 outlook that still bets on Food and Drug Administration approval for its controversial Alzheimer's treatment known as aducanumab.